Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Shukla Manojkumar Ramprasad"'
Autor:
Anand Tarage, Gopal Gole, Mandar Bhonde, Madhusudhan Reddy, Sharad Sharma, Harish Volam, Sudeep Sabde, Sanjeev Anant Kulkarni, Sadanand Mallurwar, Brahmam Sunkara, Ramesh Dattatraya Phadtare, Manoj Dandekar, Hemant Goyal, Samiron Phukan, Gayathri Sadasivam, Rupesh Kanhere, Maneesh Mehta, Nirmal Jana, Murthy Cheemala, Prashant Vidhate, Lal Dinchhana, Prashant B. Nigade, Bernstein Peter Robert, Prajakta Ahirrao, Rajan Goel, Aditya Naik, Vipul Pachpute, Sukanya Patra, Rajender Kumar Kamboj, Nilesh Mahajan, Kaustubh Tamane, Sneha Trivedi, M. K. Singh, Ajit Kumar Marisetti, Shankar Bhagwat, Mahip Verma, Atul Akarte, Dipak Lagad, Charudatt Samant, Venkata P. Palle, Vinod Patil, Anand Bokare, Dipak Modi, Chaitanya A. Kulkarni, Lakshmi Narasimham, Neetinkumar Reddy, Majid Bashir Sayyed, Sarita Koul, Shukla Manojkumar Ramprasad, Milind Gholve, Swati Tota, Vinod D. Chaudhari, Jayasagar Gundu, Manisha Shingare, Sachin J Mahangare, Shashikant Pawar
Publikováno v:
Journal of Medicinal Chemistry. 63:14700-14723
PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4614f9af4bf378b9f2f87f030837f97
https://doi.org/10.1021/acs.jmedchem.0c01264
https://doi.org/10.1021/acs.jmedchem.0c01264
